Allergan, Galderma Laboratories, L.P. and Merz Pharma are dominating the Global Dermal Fillers Market in 2019

Global Dermal Fillers Market is expected to grow at a healthy of CAGR of 10.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-dermal-fillers-market

Global dermal fillers market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in global dermal fillers market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio of the company.  

Allergan is the dominating player in the dermal fillers market. The other key players existing in the market includes Suneva Medical, Teoxane, Croma-Pharma GmbH, Sculpt Luxury Dermal Fillers LTD, Sinclair Pharma (A Subsidiary of Huadong Medicine Co., Ltd.), Anika Therapeutics, Inc., Bioxis Pharmaceuticals, BioPlus Co., Ltd., Zhejiang Jingjia Medical Technology Co.,Ltd., Galderma Laboratories, L.P., Merz Pharma, Prollenium Medical Technologies, Bioha Laboratories, Contura Ltd., Humedix.CO.LTD (Subsidiary of Huons Global) among others.

Allergan:

Allergan, headquartered in Dublin, Ireland was incorporated in 2013. The company is focused on developing, manufacturing and commercializing of various pharmaceutical, biologic, devices, surgical and regenerative medicine products.  The company is providing product under medical aesthetics, eye care, central nervous system, gastroenterology and other categories. The market focus products lie under medical aesthetics category. The company is operating in U.S. specialized therapeutics, U.S. general medicine, international, other business segments. The market focus products lay under U.S. specialized therapeutics business segment. The company is continuously engaged in manufacturing and developments of dermal fillers. 

  • In September 2019, Allergan received the U.S. FDA approval for the usage of Juvéderm Voluma XC, hyaluronic acid gel dermal filler, with TSK Steriglide cheek boost cannula to address age-related volume deficiency in the center of the face in adults over 21 years of age. The product approval will increase usage of Juvéderm Voluma XC as the dermatologists will be able to tailor approach for treatment for each patient with safety and will be able to achieve desired outcomes.  

It has its global networks through direct sales representatives and distributors in North America, South America, Europe, Asia-Pacific, Middle East and Africa through its subsidiaries in ZELTIQ Aesthetics, Inc. (U.S.), Bonti, Inc. (U.S.), Allergan Medical (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.), Oculeve, Inc. (U.S.) among others.

Galderma Laboratories, L.P.:

Galderma Laboratories, L.P. headquartered in Texas, U.S. was founded in 1981. The company offers a range of leading medical and consumer skin health brands, through three strategic areas: prescription, aesthetics, and consumer. The company is providing brands under medical solutions, consumer solutions categories. The market focused products lie under medical solutions category. The company is continuously engaged in manufacturing and developments of dermal fillers.

  • In October 2019, Galderma Laboratories, L.P. has launched seven new clinical studies to improve the beauty field. Research and development and are eager to share results relevant to several clinical studies promoting our aesthetic portfolio at the ASDS meeting where the product roadmap is set to deliver aesthetic innovations to address rising patient needs and help drive business growth.

The company has wide global presence in Asia-Pacific, Europe, Middle East, Africa, Latin America and North America

Merz Pharma:

Merz Pharma has headquartered in Frankfurt, Germany, was founded in 1908. The company focuses on providing aesthetics products to offer satisfaction and better health to patients. The company is providing product under aesthetics, neurotoxins, and regional brands categories. The market focused products lie under aesthetics category. The company is engaged in business expansion through strategic agreement of dermal fillers products.

  • In April 2019, Merz Pharma has launched the newest addition to the Belotero Revive in portfolio of dermal filler to improve hydration, elasticity and firmness of the skin, and react to the incidence of finer lines. With the new launch the company is targeting new customers concentrate particularly on consistency of the skin and the elimination of early signs of ageing and appreciates skin care and cosmetic approaches that deliver natural results. The company has wide global presence across the globe such as Europe, Asia-Pacific, Middle East, Latin America, and North America.

Recent Strategic Decisions

Dermal Fillers Market